Diabetic peripheral neuropathy (DPN) also known as Distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.
The signs and symptoms of diabetic peripheral neuropathy (DPN) include numbness, tingling, poor balance, burning pain, electric shocks, stabbing, spontaneous pain at the affected site, hypersensitive to pain against nociceptive warmth stimulation, and others.
Diagnosis of DSPN includes screening, assessment, quantitative sensory testing, nerve conduction studies, novel surrogate imaging markers of DPN, biopsy for skin and nerve fiver, optical coherence tomography, and others. Management and prevention of the DSPN generally include glycemic control, lifestyle modification, pathogenetic therapies, and pain management by using various pharmaceutical interventions.
Get FREE sample copy at:
The Diabetic Peripheral Neuropathy market report also covers emerging drugs, current treatment practices, Diabetic Peripheral Neuropathy market share of the individual therapies, current and forecasted Diabetic Peripheral Neuropathy Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Diabetic Peripheral Neuropathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Diabetic Peripheral Neuropathy Market Key Facts
The total diagnosed prevalent population of Diabetic Peripheral Neuropathy in 7MM was found to be 25,332,829 in 2017.
Among the EU5 countries, Germany has the highest prevalent cases with 3,904,730 cases in 2017, followed by Italy while the UK, on the other hand, had the lowest cases,
As per Delveinsight, Japan had 3,243,016 cases of DPN in 2017.
Among all the countries, the United States has a higher prevalent population of DPN with 12,522,483 cases in 2017. The lowest prevalent population of Diabetic Peripheral Neuropathy (DPN) was recorded in Japan.
Key Benefits of Diabetic Peripheral Neuropathy Market Report
Diabetic Peripheral Neuropathy market report provides an in-depth analysis of Diabetic Peripheral Neuropathy Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
The Diabetic Peripheral Neuropathy market report will help in developing business strategies by understanding the Diabetic Peripheral Neuropathy Market trends & developments, key players, and future market competition that will shape and drive the Diabetic Peripheral Neuropathy market in the upcoming years.
The Diabetic Peripheral Neuropathy market report covers Diabetic Peripheral Neuropathy current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Diabetic Peripheral Neuropathy market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
As per the Delveinsight, the Diabetic Peripheral Neuropathy (DPN) Market Size in the 7MM was found to be USD 2,275.52 million in 2017. Among the 7MM, the US accounts for 58% of the overall market size of DPN in 2017. While among the EU-5 countries, Germany accounts for the highest market size for DPN followed by Italy, Spain, and France
Diabetic Peripheral Neuropathy (DPN) Market Size is expected to increase during the forecast period owing to the increasing prevalent population of Diabetic Peripheral Neuropathy (DPN) patients in the 7MM, along with the advancement in the current research, which includes understanding global whole-nerve metabolism, nutrient overload, and other factors.
The Diabetic Peripheral Neuropathy market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Diabetic Peripheral Neuropathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Diabetic Peripheral Neuropathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Diabetic Peripheral Neuropathy Epidemiology
Among the gender-specific prevalent cases, in 2017, there were 5,923,135 cases of DPN in males and 6,599,349 cases in females in the US.
The Diabetic Peripheral Neuropathy epidemiology section covers insights about the historical and current Diabetic Peripheral Neuropathy patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Diabetic Peripheral Neuropathy Drugs Uptake and Key Market Players
The Diabetic Peripheral Neuropathy Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Peripheral Neuropathy market or expected to get launched in the market during the study period. The analysis covers Diabetic Peripheral Neuropathy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Diabetic Peripheral Neuropathy Companies:
And many others.
Diabetic Peripheral Neuropathy Therapies Covered in the report include:
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Diabetic Peripheral Neuropathy Competitive Intelligence Analysis
4. Diabetic Peripheral Neuropathy Market Overview at a Glance
5. Diabetic Peripheral Neuropathy Disease Background and Overview
6. Diabetic Peripheral Neuropathy Patient Journey
7. Diabetic Peripheral Neuropathy Epidemiology and Patient Population
8. Diabetic Peripheral Neuropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Diabetic Peripheral Neuropathy Unmet Needs
10. Key Endpoints of Diabetic Peripheral Neuropathy Treatment
11. Diabetic Peripheral Neuropathy Marketed Products
12. Diabetic Peripheral Neuropathy Emerging Therapies
13. Diabetic Peripheral Neuropathy Seven Major Market Analysis
14. Attribute Analysis
15. Diabetic Peripheral Neuropathy Market Outlook (7 major markets)
16. Diabetic Peripheral Neuropathy Access and Reimbursement Overview
17. KOL Views on the Diabetic Peripheral Neuropathy Market.
18. Diabetic Peripheral Neuropathy Market Drivers
19. Diabetic Peripheral Neuropathy Market Barriers
21. DelveInsight Capabilities
Diabetic Peripheral Neuropathy (DPN) Epidemiology Forecast
DelveInsight’s ‘Diabetic Peripheral Neuropathy Epidemiology Forecast-2030’ report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in the 7MM.
Diabetic Peripheral Neuropathy Pipeline Insights
Diabetic Peripheral Neuropathy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Diabetic Peripheral Neuropathy market.
Latest BioPharma Blog: Robotics In Healthcare
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd. 2432
City: Las Vegas
Country: United States